-
G1 Therapeutics' Trilaciclib Wins FDA Nod For Mitigating Chemo Effects In Lung Cancer Patients
Tuesday, February 16, 2021 - 5:37am | 180Read More...G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bone marrow) in adult patients when administered before a platinum/etoposide-containing...
-
AstraZeneca Lung Cancer Drug Gets EU Approval
Tuesday, September 1, 2020 - 4:41am | 320Read More...AstraZeneca Plc’s (NYSE: AZN) developmental drug – Imfinizi, has been approved by the European Commission after the Phase 3 clinical trial yielded positive results. What Happened: Imfinizi is the first line of treatment for adults with extensive-stage small-cell lung cancer in choice...
-
CBD And Chemotherapy-Induced Peripheral Neuropathy: What Science Tells Us
Tuesday, August 6, 2019 - 1:02pm | 610Read More...A recent study revealed research findings around chemotherapy-induced peripheral neuropathy, or CIPN, and the potential for CBD as a treatment. The study, conducted by Kannalife, a company in the Medical Marijuana Inc (OTC: MJNA) portfolio, and published in the Journal of Molecular...
-
Tesaro Shares Move Higher On Latest FDA Approval; Analyst Is 'Highly Encouraged'
Thursday, October 26, 2017 - 9:19am | 327Read More...Shares of TESARO Inc (NASDAQ: TSRO) were trading higher by nearly 2 percent early Thursday morning after the U.S. Food and Drug Administration granted approval to the company's intravenous version of its therapy to treat nausea and vomiting in adults undergoing chemotherapy. An oral version of the...
-
Endocyte Shares Up More Than 100% In 2 Days, But Analyst Sees Even More Upside Possible
Tuesday, October 3, 2017 - 1:38pm | 338Read More...Shares of Endocyte, Inc. (NASDAQ: ECYT) were trading higher by more than 60 percent Tuesday afternoon at $5.82 on top of Monday's monster triple-digit-percentage return gain, but some analysts see even more upside. Wedbush's David Nierengarten upgraded Endocyte's stock rating Neutral to Outperform...
-
Cannabinoid-Based Therapeutics Company Nemus Just Received $20 Million To Develop Its Drugs
Saturday, May 13, 2017 - 9:05pm | 1400Read More...The size of investments in the cannabis industry is rising at an unprecedented level, as evidenced by the more than $730 million raised by marijuana businesses in the four months of the year — versus $124 million in the first four months of 2016. One of the companies reaping the benefits of...
-
Exclusive: Oasmia Chairman Talks About How They're Changing Cancer Drug Delivery Treatment
Friday, August 26, 2016 - 3:25pm | 504Read More...Oasmia Pharmaceutical AB - American Depositary Shares (NASDAQ: OASM) is one of only three Swedish companies listed in the United States. While well known in Sweden, Oasmia entered the U.S. market in 2015 and is making waves in the world of oncology with a new drug delivery system that aims to...
-
Midatech Completes Acquisition Zuplenz From Galena Biopharma, Notes Potential $4.6 Billion Market
Wednesday, December 30, 2015 - 10:05am | 141Read More...Midatech Pharma PLC (NASDAQ: MTP), a small-cap nano-medicine company, announced on Wednesday it has completed the acquisition of Zuplenz from Galena Biopharma Inc (NASDAQ: GALE). Midatech will pay Galena Biopharma $3.75 million upfront with milestone payments of up to $26 million depending on...
-
Dendreon CEO On The Life-Extending Effects Of Provenge (DNDN)
Monday, March 14, 2011 - 11:16am | 112Read More...Dendreon Corp. (DNDN) CEO Mitch Gold was on CNBC this morning to discuss the success and prospects of Provenge, a cellular immunotherapy that stimulates a patient's immune system to target and attack prostate cancer. “We've been fighting the war on cancer for 40 years,” Gold said. However, Dendreon...
